Yarrow Bioscience (NASDAQ:YARW) Sees Significant Drop in Short Interest

Yarrow Bioscience (NASDAQ:YARW) saw a large decline in short interest during the month of July. As of July 31st, there was short interest totaling 12,582 shares, a decline of 93.2% from the July 15th total of 183,974 shares. Approximately 1.9% of the company’s stock are short sold. Based on an average daily volume of 38,657 shares, the short-interest ratio is currently 0.3 days.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on YARW. TD Cowen began coverage on shares of Yarrow Bioscience in a research report on Tuesday, July 28th. They set a “buy” rating on the stock. BTIG Research began coverage on Yarrow Bioscience in a report on Monday, August 3rd. They issued a “buy” rating and a $58.00 price objective for the company. Two equities research analysts have rated the stock with a Buy rating, According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $58.00.

Yarrow Bioscience Price Performance

Yarrow Bioscience stock opened at $42.94 on Wednesday. Yarrow Bioscience has a 12 month low of $14.02 and a 12 month high of $46.95.

About Yarrow Bioscience

VYNE Therapeutics Inc, a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2.